Short-term therapy of hepatic arterial infusion chemotherapy using DSM for patients with advanced hepatocellular carcinoma: pilot study
Not Applicable
Completed
- Conditions
- advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000019344
- Lead Sponsor
- Yamaguchi University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Severe coexisting illness (expect for chronic hepatitis or liver cirrhosis) 2) Active double cancers 3) Past history of hypersensitivity for drugs including iodine and contrast agent 4) Patients with pregnancy, lactation or possibility of pregnancy 5) Chronic respiratory failure 6) No hypersensitivity to DSM 7) Patients who judged as inadequacy due to other reasons by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Response, Survival, Progression-free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie DSM's efficacy in hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma?
How does short-term HAIC with DSM compare to systemic therapies like sorafenib in advanced HCC clinical outcomes?
Which biomarkers correlate with response to DSM-based HAIC in the JPRN-UMIN000019344 pilot study for advanced HCC?
What adverse events are reported in DSM hepatic arterial infusion chemotherapy for advanced HCC and their management?
Are there combination strategies involving DSM and molecularly targeted agents for advanced hepatocellular carcinoma treatment?